 ROCKVILLE, Md., July 07, 2021 GLOBE NEWSWIRE -- OpGen, Inc. Nasdaq: OPGN, OpGen or the Company, a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that the Company resumed its partially adjourned 2021 annual stockholders meeting the Annual Meeting on July 7, 2021, solely with respect to Proposal 2 set forth in its Definitive Proxy Statement, dated April 26, 2021, relating to the increase in the Companys authorized shares of common stock. The Company adjourned the Annual Meeting with respect to such proposal to provide its stockholders additional time to vote on Proposal 2. The Annual Meeting will resume with respect to Proposal 2 at 10:00 a.m. Eastern time on August 5, 2021 and will continue to be held at the Companys offices located at 9717 Key West Ave, Suite 100, Rockville, MD 20850. The record date for determining stockholders eligible to vote at the Annual Meeting will remain the close of business on April 15, 2021. 